Abstract
The assembly of naturally occurring amyloid peptides into cytotoxic oligomeric and fibrillar aggregates is believed to be a major pathologic event in over 25 human diseases. Blocking of or interfering with the aggregation of amyloid peptides such as amyloid-β (Aβ) using small organic molecules, peptides and peptidomimetics, and nanoparticles that selectively bind or inhibit Aβ aggregates is a promising strategy for the development of novel pharmaceutical approaches and agents to treat Alzheimer's disease (AD). In a broad sense, considering many common features in structure, kinetics, and biological activity of amyloid peptides, potent inhibitors and associated inhibition strategies that are developed for targeting Aβ aggregation could also be generally applied to other amyloid-forming peptides in “protein-aggregation diseases”. Due to the complex nature of Aβ self-assembly process, increasing knowledge in high-resolution structures of Aβ oligomers, atomic-level Aβ-inhibitor binding information, and cost-effective high-throughput screening method will improve our fundamental understanding of amyloid formation and inhibition mechanisms, as well as practical design of pharmaceutical strategies and drugs to treat AD. This review summarizes major findings, recent advances, and future challenges for the development of new Aβ-aggregation inhibitors, mainly focusing on three major classes of Aβ inhibitors with associated inhibition mechanisms and practical examples.
Keywords: Amyloid-beta, Amyloid inhibitor, Amyloid toxicity, Protein aggregation, Alzheimer disease.
Current Pharmaceutical Design
Title:Inhibition of Amyloid-β Aggregation in Alzheimer's Disease
Volume: 20 Issue: 8
Author(s): Qiuming Wang, Xiang Yu, Lingyan Li and Jie Zheng
Affiliation:
Keywords: Amyloid-beta, Amyloid inhibitor, Amyloid toxicity, Protein aggregation, Alzheimer disease.
Abstract: The assembly of naturally occurring amyloid peptides into cytotoxic oligomeric and fibrillar aggregates is believed to be a major pathologic event in over 25 human diseases. Blocking of or interfering with the aggregation of amyloid peptides such as amyloid-β (Aβ) using small organic molecules, peptides and peptidomimetics, and nanoparticles that selectively bind or inhibit Aβ aggregates is a promising strategy for the development of novel pharmaceutical approaches and agents to treat Alzheimer's disease (AD). In a broad sense, considering many common features in structure, kinetics, and biological activity of amyloid peptides, potent inhibitors and associated inhibition strategies that are developed for targeting Aβ aggregation could also be generally applied to other amyloid-forming peptides in “protein-aggregation diseases”. Due to the complex nature of Aβ self-assembly process, increasing knowledge in high-resolution structures of Aβ oligomers, atomic-level Aβ-inhibitor binding information, and cost-effective high-throughput screening method will improve our fundamental understanding of amyloid formation and inhibition mechanisms, as well as practical design of pharmaceutical strategies and drugs to treat AD. This review summarizes major findings, recent advances, and future challenges for the development of new Aβ-aggregation inhibitors, mainly focusing on three major classes of Aβ inhibitors with associated inhibition mechanisms and practical examples.
Export Options
About this article
Cite this article as:
Wang Qiuming, Yu Xiang, Li Lingyan and Zheng Jie, Inhibition of Amyloid-β Aggregation in Alzheimer's Disease, Current Pharmaceutical Design 2014; 20 (8) . https://dx.doi.org/10.2174/13816128113199990068
DOI https://dx.doi.org/10.2174/13816128113199990068 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Taking Down the Unindicted Co-Conspirators of Amyloid β-Peptidemediated Neuronal Death: Shared Gene Regulation of BACE1 and APP Genes Interacting with CREB, Fe65 and YY1 Transcription Factors
Current Alzheimer Research Neurotransmitter Imaging: Basic Concepts and Future Perspectives
Current Medical Imaging It is Now Personal: Recent Views on the Assessment of Therapeutic Infidelity in Severe Mental Illness
Current Clinical Pharmacology Anticoagulant Therapy for Acute Lung Injury or Pneumonia
Current Drug Targets Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
Current Pharmaceutical Design Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products
Current Neuropharmacology Inside the Neurobiological Complexity of Antisocial Personality Disorder
Current Psychiatry Reviews Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry Transporters in the Brain Endothelial Barrier
Current Medicinal Chemistry Editorial (Thematic Issue: Current Perspectives and Challenges in Design, Chemistry and Pharmacology of Opioids)
Current Pharmaceutical Design Effect of Replacing Phenylalanine Residues by Para-Substituted Phenylalanines on the Aggregation Behavior of Aβ16-22
Protein & Peptide Letters Caffeoylquinic Acids with Potential Biological Activity from Plant In vitro Cultures as Alternative Sources of Valuable Natural Products
Current Pharmaceutical Design Gestational Exposure to Serotonin Reuptake Inhibitors and Pregnancy Outcome; Exploring the Role of Bias and Confounders
Current Neuropharmacology An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins
Current Molecular Medicine Progress in the Search for New Dopamine Transporter Inhibitors
Current Medicinal Chemistry Cytokines in Neuroinflammation and Alzheimers Disease
Current Drug Targets Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature
Reviews on Recent Clinical Trials Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development
Current Topics in Medicinal Chemistry